| Autor: |
Hunter AM; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Itzykson R; Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, Centre National de la Recherche Scientifique, Paris, France.; Département Hématologie et Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Mesa R; Hematology and Medical Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC., Karanes C; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Li Y; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., de Claro RA; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Norsworthy KJ; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Theoret M; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD., Pulte E; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD., Padron E; Hematologic Malignancies. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. |
